Silk Road Medical, Inc. operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was founded in 2007 and is headquartered in Sunnyvale, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone408-720-9002
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$34.56 million
Profitability
Miscellaneous
Employees176
Next Earnings Date11/4/2019 (Estimated)
OptionableNot Optionable
Silk Road Medical (NASDAQ:SILK) Frequently Asked Questions
What is Silk Road Medical's stock symbol?
Silk Road Medical trades on the NASDAQ under the ticker symbol "SILK."
How were Silk Road Medical's earnings last quarter?
Silk Road Medical Inc (NASDAQ:SILK) released its earnings results on Monday, July, 29th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.14. The business earned $14.93 million during the quarter, compared to analysts' expectations of $13.64 million. Silk Road Medical's quarterly revenue was up 92.2% compared to the same quarter last year. View Silk Road Medical's Earnings History.
When is Silk Road Medical's next earnings date?
What guidance has Silk Road Medical issued on next quarter's earnings?
Silk Road Medical updated its FY 2019 earnings guidance on Monday, July, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $60-62 million, compared to the consensus revenue estimate of $60.17 million.
What price target have analysts set for SILK?
5 equities research analysts have issued 12-month price objectives for Silk Road Medical's shares. Their forecasts range from $40.01 to $52.00. On average, they expect Silk Road Medical's share price to reach $44.8020 in the next twelve months. This suggests a possible upside of 26.8% from the stock's current price. View Analyst Price Targets for Silk Road Medical.
What is the consensus analysts' recommendation for Silk Road Medical?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silk Road Medical in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Silk Road Medical.
Has Silk Road Medical been receiving favorable news coverage?
Press coverage about SILK stock has trended somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Silk Road Medical earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Silk Road Medical.
Are investors shorting Silk Road Medical?
Silk Road Medical saw a decline in short interest in August. As of August 31st, there was short interest totalling 728,400 shares, a decline of 18.7% from the July 31st total of 895,500 shares. Based on an average trading volume of 274,900 shares, the short-interest ratio is presently 2.6 days. Approximately 4.6% of the company's stock are short sold. View Silk Road Medical's Current Options Chain.
Who are some of Silk Road Medical's key competitors?
Some companies that are related to Silk Road Medical include Cantel Medical (CMD), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI), Nevro (NVRO), Glaukos (GKOS), Irhythm Technologies (IRTC), Cardiovascular Systems (CSII), Merit Medical Systems (MMSI), Atrion (ATRI), Cryolife (CRY), AtriCure (ATRC), Luminex (LMNX), Orthofix Medical (OFIX) and Tactile Systems Technology (TCMD).
What other stocks do shareholders of Silk Road Medical own?
Who are Silk Road Medical's key executives?
Silk Road Medical's management team includes the folowing people:
- Ms. Erica J. Rogers, Chief Exec. Officer, Pres & Director (Age 55)
- Mr. Lucas W. Buchanan, Chief Financial Officer (Age 41)
- Mr. Robert A. Nicholas, VP of Operations & Engineering (Age 56)
- Mr. Andrew S. Davis, Exec. VP of Global Sales & Marketing (Age 50)
- Ms. Alison Highlander, VP of HR
When did Silk Road Medical IPO?
(SILK) raised $75 million in an initial public offering (IPO) on Thursday, April 4th 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.
When does Silk Road Medical's lock-up period expire?
Silk Road Medical's lock-up period expires on Tuesday, October 1st. Silk Road Medical had issued 6,000,000 shares in its IPO on April 4th. The total size of the offering was $120,000,000 based on an initial share price of $20.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.
Who are Silk Road Medical's major shareholders?
Silk Road Medical's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Warburg Pincus LLC (39.77%), Norwest Venture Partners Xiii LP (8.03%), Vanguard Group Inc. (1.73%), Jennison Associates LLC (1.39%), TimesSquare Capital Management LLC (1.26%) and Janus Henderson Group PLC (1.26%). Company insiders that own Silk Road Medical stock include Pincus & Co Warburg and X Finance LP Wp. View Institutional Ownership Trends for Silk Road Medical.
Which major investors are buying Silk Road Medical stock?
SILK stock was purchased by a variety of institutional investors in the last quarter, including Warburg Pincus LLC, Norwest Venture Partners Xiii LP, Vanguard Group Inc., Jennison Associates LLC, TimesSquare Capital Management LLC, Janus Henderson Group PLC, Janus Henderson Group PLC and BlackRock Inc.. View Insider Buying and Selling for Silk Road Medical.
How do I buy shares of Silk Road Medical?
Shares of SILK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Silk Road Medical's stock price today?
One share of SILK stock can currently be purchased for approximately $35.33.
How big of a company is Silk Road Medical?
What is Silk Road Medical's official website?
How can I contact Silk Road Medical?
Silk Road Medical's mailing address is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. The company can be reached via phone at 408-720-9002 or via email at [email protected]
MarketBeat Community Rating for Silk Road Medical (NASDAQ SILK)
MarketBeat's community ratings are surveys of what our community members think about Silk Road Medical and other stocks. Vote "Outperform" if you believe SILK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SILK will underperform the S&P 500 over the long term. You may vote once every thirty days.
